Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Petmed Express (PETS) Share Price
News stories about Petmed Express (NASDAQ:PETS) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Petmed Express earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.4388310258938 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern’s analysis:
- Petmed Express Inc (PETS) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
- Why CTI BioPharma, PetMed Express, and Pfizer Slumped Today (finance.yahoo.com)
- Notable Monday Option Activity: NFLX, SFLY, PETS (nasdaq.com)
- Analyst: Dump This Drug Stock Now (schaeffersresearch.com)
- Land on 5 Top-Ranked Profitable Stocks Via DuPont Analysis (finance.yahoo.com)
Petmed Express traded up $1.14, reaching $38.99, on Friday, according to MarketBeat.com. The stock had a trading volume of 796,743 shares, compared to its average volume of 655,032. Petmed Express has a 12-month low of $31.81 and a 12-month high of $57.80. The stock has a market capitalization of $803.23 million, a price-to-earnings ratio of 21.42, a PEG ratio of 1.71 and a beta of 0.98.
Several research analysts recently issued reports on PETS shares. BidaskClub cut shares of Petmed Express from a “hold” rating to a “sell” rating in a report on Tuesday, April 24th. ValuEngine raised shares of Petmed Express from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Petmed Express from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a report on Wednesday, May 9th. Craig Hallum reduced their target price on shares of Petmed Express to $38.00 and set a “hold” rating for the company in a report on Tuesday, May 8th. Finally, CL King started coverage on shares of Petmed Express in a report on Friday, June 15th. They set a “neutral” rating for the company. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $38.80.
In other news, Director Frank J. Formica sold 5,000 shares of the business’s stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $41.78, for a total transaction of $208,900.00. Following the completion of the sale, the director now owns 48,500 shares of the company’s stock, valued at $2,026,330. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by insiders.
About Petmed Express
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes.
Recommended Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.